Abstract
The universal prevalence of hepatitis C virus (HCV) infection, which causes chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma, has become a significant health problem worldwide. Interferon-based therapies, the current standard, IFN-based therapies have limited efficacy and undesirable adverse effects. In addition, neither vaccination against HCV nor specific antiviral reagents for HCV are yet available. Thus, a major medical need still exists for novel and more efficacious anti-HCV reagents showing broad-spectrum clinical efficacy with enhanced tolerability. With the progress in our current understanding of the function and regulation of HCV gene products, the three-dimensional structures of virally encoded enzymes and the recent establishment of the HCV-replicon system, several pharmacological targets are being studied for HCV therapy, including cellular receptors mediating HCV entry, factors facilitating HCV replication and assembly, and intracellular pathways. Recently developed mouse models will be very helpful in evaluating the in vivo efficacy of novel antiviral reagents. Currently many novel antiviral drugs are under evaluation in clinical trials. This review will comprehensively discuss the current treatment options and various novel antiviral reagents available. Ongoing clinical studies of promising lead drugs are also reviewed.
Keywords: Hepatitis C virus, therapy, target, inhibitor, effectiveness, safety, resistance, clinical studies
Current Molecular Pharmacology
Title: Emerging Therapeutic Strategies for Hepatitis C Virus Infection
Volume: 1
Author(s): Ken Sato, Hitoshi Takagi, Takeshi Ichikawa, Satoru Kakizaki and Masatomo Mori
Affiliation:
Keywords: Hepatitis C virus, therapy, target, inhibitor, effectiveness, safety, resistance, clinical studies
Abstract: The universal prevalence of hepatitis C virus (HCV) infection, which causes chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma, has become a significant health problem worldwide. Interferon-based therapies, the current standard, IFN-based therapies have limited efficacy and undesirable adverse effects. In addition, neither vaccination against HCV nor specific antiviral reagents for HCV are yet available. Thus, a major medical need still exists for novel and more efficacious anti-HCV reagents showing broad-spectrum clinical efficacy with enhanced tolerability. With the progress in our current understanding of the function and regulation of HCV gene products, the three-dimensional structures of virally encoded enzymes and the recent establishment of the HCV-replicon system, several pharmacological targets are being studied for HCV therapy, including cellular receptors mediating HCV entry, factors facilitating HCV replication and assembly, and intracellular pathways. Recently developed mouse models will be very helpful in evaluating the in vivo efficacy of novel antiviral reagents. Currently many novel antiviral drugs are under evaluation in clinical trials. This review will comprehensively discuss the current treatment options and various novel antiviral reagents available. Ongoing clinical studies of promising lead drugs are also reviewed.
Export Options
About this article
Cite this article as:
Sato Ken, Takagi Hitoshi, Ichikawa Takeshi, Kakizaki Satoru and Mori Masatomo, Emerging Therapeutic Strategies for Hepatitis C Virus Infection, Current Molecular Pharmacology 2008; 1 (2) . https://dx.doi.org/10.2174/1874467210801020130
DOI https://dx.doi.org/10.2174/1874467210801020130 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural and Induced Antibody Polyreactivity
Anti-Cancer Agents in Medicinal Chemistry Medicinal Chemistry of Drugs with Active Metabolites Following Conjugation
Mini-Reviews in Medicinal Chemistry Preface [Hot Topic: Transcription Factors as Targets of Novel Therapeutic Approaches of Autoimmune Diseases (Executive Editor: Gunther Ne)]
Current Pharmaceutical Design Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Heterogeneity in the CD4 T Cell Compartment and the Variability of Neonatal Immune Responsiveness
Current Immunology Reviews (Discontinued) Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect of Aging On Angiogenesis and Arteriogenesis
Current Cardiology Reviews Review of the Currently Available Systems to Obtain Platelet Related Products to Treat Equine Musculoskeletal Injuries
Recent Patents on Regenerative Medicine Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Quantitative Structure - Activity Relationship (QSAR) Studies on Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
Current Medicinal Chemistry B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Cystic Fibrosis and the Innate Immune System: Therapeutic Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Current or New Cytomegalovirus Antivirals and Novel Animal Model Strategies
Inflammation & Allergy - Drug Targets (Discontinued) Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies
Current Drug Delivery Lipid-Based Nanocarriers for Cutaneous Leishmaniais and Buruli Ulcer Management
Current Pharmaceutical Design Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
Current Pharmaceutical Design Feline Immunodeficiency Virus Model for Designing HIV/AIDS Vaccines
Current HIV Research Molecular Targets of FoxP3+ Regulatory T Cells
Mini-Reviews in Medicinal Chemistry